NCT02779959

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Headache is a common presenting complaint to the emergency department accounting for 1-2% of patient visits. Of these headaches, approximately 90% are migraine, tension headache, or combined presentations. The most commonly used migraine therapy in the ED is intravenous prochlorperazine, but its administration requires close nursing observation, a bed, and the insertion of an intravenous catheter. Buccal prochlorperazine represents an alternative form of delivery that enables rapid achievement of therapeutic blood levels and may lead to symptom resolution. In a randomized, controlled, prospective study,the investigators plan to assess the efficacy of buccal versus intravenous prochlorperazine for the initial emergency department treatment of migraine headaches.

Conditions

• Migraine Disorders

Interventions

Type	Name	Description
DRUG	Prochlorperazine

Timeline

• Start date: 2016-04-01
• Primary completion: 2017-10-01
• Completion: 2018-04-01
• First posted: 2016-05-23
• Last updated: 2018-01-05

Locations

1 site across 1 country: United States